Tags : apremilast

Pharma

Amgen to Acquire Celgene’s Otezla (apremilast) for $13.4B

Shots: Amgen to acquire Otezla for $13.4B in cash and will receive its related intellectual property including patents primarily covering apremilast with all assets and liabilities related to Otezla along with Celgene’s employees associated with the Otezla BMS to divest Otezla in order to get regulatory approval for its pending Celgene merger. The closing of […]Read More